Senses Disorder TRIZ Cases

Humanized antibodies bind beta-amyloid epitopes to inhibit aggregation, reducing plaque burden while minimizing immunogenic side effects.

Culturing pluripotent stem cells with MEK and Nodal inhibitors to generate retinal pigment epithelial cells.

CXCR4 inhibitor compounds resist inflammatory processes to treat ocular disorders where early-stage intervention remains ineffective.

A 2 mL syringe with a 27G needle reduces injection force and time for high viscosity omalizumab formulations.

Beta amino acid derivatives bind multiple integrins simultaneously, resolving the trade-off between single-target specificity and broad therapeutic efficacy.

Structural modifications to the diadamantyl core yield selective HSD1 inhibitors with improved pharmacokinetic profiles for treating diabetes and obesity.

Novel indazolyl ester or amide derivatives modulate the glucocorticoid receptor with enhanced affinity and specificity.

5-(carboxamide)-1-pyridinyl-1,2,4-triazole derivatives act as potent V1a receptor antagonists.

Modifying homoharringtonine via acylation improves anti-tumor efficacy while reducing toxicity compared to the parent compound.

Novel heterocyclic prolinamide derivatives inhibit HTRA1 protease activity to prevent and treat age-related macular degeneration.

Dimethyl trisulfide converts cyanide ions to thiocyanate via intramuscular injection.

A multilayer thin film device positions a bioactive agent between polymer layers to elute medication into ocular tissue.

Formula I compound suppresses drusen formation via preliminary action, preventing atrophic macular degeneration progression.

Developing ALDH agonists increases enzymatic oxidation of cytotoxic aldehydes, addressing inadequate detoxification in neurodegenerative and liver diseases.

Targeting Plpp7 and Fam126a inhibitors enables direct in situ transdifferentiation, resolving low conversion efficiency hurdles.

Administering hypoxia mimetics reduces oxygen levels below five percent, activating HIF pathways to restore tear secretion and stability.

Single bicyclic molecules merge beta2 agonist and M3 antagonist functions to reduce formulation complexity while maintaining therapeutic efficacy.

Optimized hydantoin structures balance channel inhibition efficacy with selectivity profiles for CNS applications.

Removing the Fc region from biparatopic polypeptides reduces microhemorrhage risks while maintaining amyloid plaque clearance.

Photopolymerizable ocular composition forms a crosslinked matrix to embed therapeutic agents at high concentrations.

Segmented bicyclic heteroaryls target PI3Kδ to resolve isoform discrimination limits in inflammatory disease research.

Small molecule inhibitors selectively bind MASP-2 active sites to block the lectin pathway while preserving classical complement activation.

Dock-and-Lock technology attaches PEG to interferon domains, resolving the trade-off between extended serum half-life and site-specific manufacturing precision.

Triazinone derivatives inhibit GSK3-beta to treat neurodegenerative diseases, addressing the lack of effective inhibitors in current therapies.

Short interfering RNA targets inflammatory genes to suppress airway inflammation, addressing inadequate symptom relief in allergic disease treatments.

Humanized 16D3 antibodies reduce tumor size and vascularization while minimizing immunogenic side effects.

Amido thiadiazole derivatives constrain NADPH oxidase power, reducing reactive oxygen species to treat oxidative stress disorders.

Formula I compounds inhibit multiple receptor tyrosine kinases to overcome insufficient therapeutic effects from single pathway targeting.

An oral pharmaceutical composition containing rebamipide stimulates mucous secretion and inhibits ocular surface damage.

Converting the free base into mesylate or sulphate salts raises melting points to prevent particle clumping during tablet pressing.

Segmented peptide and antibody therapy resolves low binding affinity by enabling precise amyloid targeting and efficient deposit removal.

Pyridine derivatives inhibit ALK-5 and ALK-4 receptors, reducing extracellular matrix production in pulmonary and liver fibrosis.

Formula I compounds inhibit protein kinase C activity through specific structural substituents.

Polysaccharide derivatives esterified with lipoic acid provide moisturizing and elasticizing properties.

Maple leaf extract treats corneal diseases by inhibiting angiogenesis, avoiding the hemorrhage and retinal detachment risks of steroidal injections.

Hydrophilic pro-drug derivatives and extended release compositions improve retinal drug delivery while reducing side effects from high systemic doses.

Novel beta2 adrenergic receptor agonists resolve limitations in current therapies by delivering enhanced potency, selectivity, and duration of action.

Ultrasonic cavitation homogenizes viscous hydrogels, eliminating heat generation and microbial contamination risks.

An injectable bioabsorbable copolymer formulation forms a solid gel structure to sustain release of bioactive agents.

A bi-modal hyaluronate formulation combines distinct molecular mass fractions to create a single viscoelastic agent with controlled rheological properties.

A biodegradable intraocular implant releases prostamide compounds to lower eye pressure.

Specific structural features enable high selectivity for BACE-1, reducing Aβ peptide accumulation and halting disease progression.